🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Paul Tudor Jones’s ARQT Holdings & Trades

First Buy
Q3 2022
Duration Held
17 Quarters
Largest Add
Q1 2024
+204,779 Shares
Current Position
15,357 Shares
$405,886 Value

Paul Tudor Jones's ARQT Position Overview

Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 15,357 shares of Arcutis Biotherapeutics, Inc. (ARQT) worth $405,886, representing 0.00% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 17 quarters.

Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ARQT, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2024, adding 204,779 shares. Largest reduction occurred in Q2 2024, reducing 204,779 shares.

Analysis based on 13F filings available since 2013 Q2

Paul Tudor Jones's Arcutis Biotherapeutics (ARQT) Holding Value Over Time

Track share changes against reported price movement

Quarterly Arcutis Biotherapeutics (ARQT) Trades by Paul Tudor Jones

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q3 2026 -116,557 Reduce 88.36% 15,357 $26.43
Q2 2026 +131,914 New Buy 131,914 $26.22
Q1 2026 -106,134 Sold Out 0 $0.00
Q4 2025 +36,154 Add 51.66% 106,134 $29.04
Q3 2025 +69,980 New Buy 69,980 $18.85
Q2 2025 -103,373 Sold Out 0 $0.00
Q1 2025 +39,039 Add 60.68% 103,373 $15.64
Q4 2024 +43,370 Add 206.88% 64,334 $13.93
Q3 2024 +20,964 New Buy 20,964 $9.30
Q2 2024 -204,779 Sold Out 0 $0.00
Q1 2024 +204,779 New Buy 204,779 $9.91
Q4 2023 -45,461 Sold Out 0 $0.00
Q3 2023 +45,461 New Buy 45,461 $5.31
Q2 2023 -30,306 Sold Out 0 $0.00
Q1 2023 +30,306 New Buy 30,306 $0.01
Q4 2022 -18,349 Sold Out 0 $0.00
Q3 2022 +18,349 New Buy 18,349 $19.13

Paul Tudor Jones's Arcutis Biotherapeutics Investment FAQs

Paul Tudor Jones first purchased Arcutis Biotherapeutics, Inc. (ARQT) in Q3 2022, acquiring 18,349 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Paul Tudor Jones has held Arcutis Biotherapeutics, Inc. (ARQT) for 17 quarters since Q3 2022.

Paul Tudor Jones's largest addition to Arcutis Biotherapeutics, Inc. (ARQT) was in Q1 2024, adding 204,779 shares worth $2.03 M.

According to the latest 13F filing for Q3 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 15,357 shares of Arcutis Biotherapeutics, Inc. (ARQT), valued at approximately $405,886.

As of the Q3 2026 filing, Arcutis Biotherapeutics, Inc. (ARQT) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.

Paul Tudor Jones's peak holding in Arcutis Biotherapeutics, Inc. (ARQT) was 204,779 shares, as reported at the end of Q1 2024.